ENTA Competitors & Alternatives

Compare Enanta Pharmaceuticals Inc with similar stocks in the same industry

Biotechnology

ENTA

Main Stock
$10.79
-1.82%
Tradestie Score
46
Market Cap
$226.82M
Revenue Growth
-21.6%
Analyst Upside
+102.3%

Supply-Chain & Ecosystem Map (Customers, Suppliers & Direct Competitors)

Bottleneck Score: 2/10 Drug Discovery Biotech Drug Design
Competitive Moat: None
Core Technology Stack: small molecule drug design, protease inhibitors
Major Customers 3
AbbVie pharmaceutical partners research institutions
Critical Suppliers 3
CROs chemical manufacturers lab equipment providers
Direct Ecosystem Rivals 3

Top Competitors

217 stocks in Biotechnology
Company Price Market Cap P/E Score Action
CAPR Capricor Therapeutics Inc
$8.45
-11.39%
$357.51M - 28 Compare
DMAC DiaMedica Therapeutics Inc. Common Stock
$8.39
-4.55%
$354.59M - 48 Compare
CGEM Cullinan Therapeutics, Inc. Common Stock
$9.65
-6.13%
$354.45M - 47 Compare
LBRX LB Pharmaceuticals Inc Common Stock
$43.04
+0.07%
$353.70M - 36 Compare
ANNX Annexon, Inc. Common Stock
$3.63
-7.53%
$332.96M - 46 Compare
REPL Replimune Group, Inc.
$21.56
-1.51%
$328.62M - 26 Compare
EPRX Eupraxia Pharmaceuticals Inc. Common Stock
$7.54
-7.48%
$307.12M - 32 Compare
CADL Candel Therapeutics, Inc. Common Stock
$6.09
-1.85%
$304.12M - 47 Compare
JBIO Jade Biosciences, Inc. Common Stock
$15.52
-3.87%
$297.23M - 36 Compare
OMER Omeros Corporation
$17.18
-1.80%
$281.75M 14.9 55 Compare

Data updated: Nov 16, 2026 | Industry: Biotechnology (SIC 2834)

217 stocks in this industry